MCL1 and ovarian carcinoma: To analyse if Mcl-1 decrease upon BAPTA-AM treatment involves proteasomal degradation, we incubated ovarian carcinoma cells with bortezomib, a proteasome inhibitor, for 1 h and then treated cells with BAPTA-AM for 6 h.